JAMA Pediatrics,
This Viewpoint discusses controversies surrounding the US Food and Drug Administration's 2016 approval of eteplirsen for…
This Viewpoint discusses controversies surrounding the US Food and Drug Administration's 2016 approval of eteplirsen for…
This Viewpoint discusses controversies surrounding the US Food and Drug Administration's 2016 approval of eteplirsen for…
For now, eteplirsen has provided a worrisome model for the next generation of molecularly targeted therapies: demonstrate a…
http://jamanetwork.com/journals/jama/article-abstract/2572614
This Viewpoint discusses controversies surrounding the US Food and Drug Administration’s 2016 approval of eteplirsen for…
“Speeding drugs to market based on biomarker outcomes [such as muscular dystrophin levels] can actually lead to a worse outcome…
This doesn't bode well for safer less expensive drugs from the FDA. We need to end the corrupting influence of money on politics.
This Viewpoint discusses controversies surrounding the US Food and Drug Administration’s 2016 approval of eteplirsen for…
Implications of the FDA Approval of Eteplisen for Muscular Dystrophy
This Viewpoint discusses controversies surrounding the US Food and Drug Administration's 2016 approval of eteplirsen for…
This Viewpoint discusses controversies surrounding the US Food and Drug Administration's 2016 approval of eteplirsen for…
This Viewpoint discusses controversies surrounding the US Food and Drug Administration's 2016 approval of eteplirsen for…
This Viewpoint discusses controversies surrounding the US Food and Drug Administration's 2016 approval of eteplirsen for…
This Viewpoint discusses controversies surrounding the US Food and Drug Administration's 2016 approval of eteplirsen for…
Patients with Duchenne muscular dystrophy (DMD), need better treatments, and drugs like eteplirsen might one day fill that role.